OXFORD BIOMEDICA
Oxford Biomedica Appoints
Dr Peter Johnson as Chairman
Oxford, UK -2
January 2001: Oxford BioMedica ("BioMedica") announced today that
Dr Peter Johnson, currently a non-executive director of the Company,
has been appointed non-executive chairman. He replaces Mr Alan Goodman
who is retiring as a director of BioMedica.
Dr Johnson
(BSc, PhD, FRSC, FIBiol, FRCPath), joined the board of BioMedica
as a non-executive director on 26 July 1999. He has extensive drug
research and development experience with Wellcome, Hoechst and Astra.
He was formerly chairman and managing director of Smith Kline and
French Research Limited and director of pharmaceutical research
and development and group main board director of Fisons Plc. He
was a non-executive director of Quadrant Healthcare plc until December
2000 and is currently chairman of CBAMS Limited and Sterix Limited.
Mr Goodman,
a founder of BioMedica, has served as a non-executive director for
over four years and has been chairman since 29 June 1998. He is
leaving BioMedica to concentrate on expanding his activities with
Avlar BioVentures Ltd, the biotech investment fund for new biotech
ventures.
Commenting
on the announcement, Professor Alan Kingsman, Chief Executive of
Oxford BioMedica, said:
"We are all delighted that Peter has agreed to take the Chair
of BioMedica. As the Company matures and progresses more and more
towards advanced product development, Peter's extensive experience
of the industry will be invaluable. We thank Alan Goodman for his
key contribution to the establishment of BioMedica as a world-class
gene-based company and we wish him well in his expanding activities
with Avlar in starting new biotech ventures. Alan will remain a
corporate advisor to the Company."
Return to the
News
Notes
to Editors
- Oxford
BioMedica plc
Established in 1995, the Company specialises in the development
and application of gene-based therapeutics and immunotherapeutics
for the treatment of disease in the areas of Oncology, Neurobiology
and Viral Infection and in Gene Discovery. Oxford BioMedica plc
was floated on the Alternative Investment Market of the London
Stock Exchange in December 1996.
Currently
Oxford BioMedica has corporate collaborations with Aventis, AstraZeneca,
IDM, Modex Therapeutics, Nycomed Amersham, Valentis and Virbac.
BioMedica has two products in Phase I/II clinical trials. MetXiaŽ
is in clinical trials for late-stage breast cancer (BC1) and ovarian
cancer (OC1) and TroVaxT is in clinical trials for late-stage
colorectal cancer.
| For
further information please contact: |
|
|
Oxford BioMedica plc
Professor Alan
Kingsman, Chief Executive |
Tel:
+44 (0)1865 783 000 |
| City/Financial
Enquiries
David
Simonson, Melanie Toyne Sewell
Merlin Financial Communications |
Tel:
+44 (0)20 7606 1244 |
| Scientific/Trade
Enquiries
Chris
Gardner, HCC•De Facto Group |
Tel:
+44 (0)20 7496 3300 |
|
